Cabaletta Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on the stock and has a $16.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors that support both the clinical and commercial potential of Cabaletta Bio’s rese-cel program. The long-term manufacturing partnership with Cellares is expected to deliver large-scale, cost-effective autologous CAR-T production, including multiple doses from a single blood draw, which should support broader use across several autoimmune indications and enhance pricing competitiveness.
Tsao also highlights encouraging early clinical data showing that rese-cel can be administered without pre-conditioning while still achieving meaningful B-cell depletion, disease activity reductions, and a favorable safety profile in pemphigus vulgaris patients. Together with a highly reliable manufacturing success rate and upcoming lupus data that could underpin pivotal trial discussions with the FDA, these elements underpin his unchanged $16 price target and reinforce his positive view on the stock’s risk‑reward profile.